Literature DB >> 22399111

[Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].

W Leicht1, C Hampel, J Thüroff.   

Abstract

Idiopathic detrusor overactivity (motory urge) negatively affects the live of patients. Conservative treatment is not always effective and has multiple side effects. Sacral neuromodulation is a second line therapy for the treatment of idiopatic detrusor overactivity. Over the last decade, botulinum toxin injections have been increasingly used as alternative although there are only few randomized studies. Goal of this review is to compare efficiacy, safety and cost effectiveness of both methods.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22399111     DOI： 10.1007/s00120-012-2819-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  24 in total

1.  A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.

Authors:  Govindaraj N Rajkumar; Douglas R Small; Abdul W Mustafa; Graeme Conn
Journal:  BJU Int       Date:  2005-10       Impact factor: 5.588

2.  Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience.

Authors:  Adonis Hijaz; Sandip P Vasavada; Firouz Daneshgari; Hasan Frinjari; Howard Goldman; Raymond Rackley
Journal:  Urology       Date:  2006-09-18       Impact factor: 2.649

3.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

4.  [Subjective patient satisfaction after injection of botulinum-a toxin in detrusor overactivity].

Authors:  H Schulte-Baukloh; C Weiss; J Schobert; T Stolze; B Stürzebecher; H H Knispel
Journal:  Aktuelle Urol       Date:  2005-06       Impact factor: 0.658

5.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

6.  Medium-term experience of sacral neuromodulation by tined lead implantation.

Authors:  Anco C Van Voskuilen; Dennis J A J Oerlemans; Ernest H J Weil; Ubi van den Hombergh; Philip E V A van Kerrebroeck
Journal:  BJU Int       Date:  2006-09-06       Impact factor: 5.588

7.  Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.

Authors:  Gilles Karsenty; Ehab Elzayat; Thomas Delapparent; Benoît St-Denis; Marie-Claude Lemieux; Jacques Corcos
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

8.  Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding.

Authors:  Jan Groen; J L H Ruud Bosch; Ron van Mastrigt
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

9.  Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

Authors:  Arun Sahai; Mohammad Shamim Khan; Prokar Dasgupta
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

10.  Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.

Authors:  Vinay Kalsi; Apostolos Apostolidis; Roshni Popat; Gwendoline Gonzales; Clare J Fowler; Prokar Dasgupta
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096
View more
  1 in total

1.  Urodynamic characterization of lower urinary tract symptoms in men less than 40 years of age.

Authors:  Asha E Jamzadeh; Donghua Xie; Melissa Laudano; Stephan Seklehner; Dean S Elterman; Lucien Shtromvaser; Richard Lee; Steven A Kaplan; Alexis E Te; Bilal Chughtai
Journal:  World J Urol       Date:  2013-07-25       Impact factor: 4.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.